1. Kamoun A, De Reyniès A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 June; 77(4):420-423. DOI: 10.1016/j.eururo.2019.09.006.
2. Yanagisawa T, Miki J, Sakanaka K, et al. MP73-03 clinical significance of horizontal and vertical margin of OF EN-BLOC TURBT specimen. J Urol. 2020 April; 203:1121-1122. DOI: 10.1097/JU.0000000000000959.03.
3. Sathianathen N, Gantz J, Alarid-Escudero F, et al. MP73-07 intravesical chemotherapy for low grade bladder cancer: a cost analysis. J Urol. 2020 April; 203:1123-1124. DOI: 10.1097/JU.0000000000000959.07
4. Adele Caruso A, Ravishankar R, VanArsdalen K, et al. MP73-08 intravesical gemcitabine and docetaxol in heavily PRE-TREATED patients with non-muscle invasive bladder cancer (NMIBC). J Urol. 2020 April; 203:1123-1124. DOI: 10.1097/JU.0000000000000959.08
5. Herr H. PD51-04 bladder – sparing surgery (BSS) for muscle invasive bladder cfncer (MIBC) after complete response to neoadjuvant chemotherapy (NAC). J Urol. 2020 April; 203:1084. DOI: 10.1097/JU.0000000000000953.04
6. Kool R, Marcq G, Busca J, et al. PD60-01 definitive radiation-based therapy for muscle-invasive bladder cancer: the Canadian multicenter experience. J Urol. 2020 April; 203:1273. DOI: 10.1097/JU.0000000000000977.01.
7. Shou J, Cao C, Jiang W, et al. PD51-07 oncologic and functional effectiveness of neoadjuvant chemotherapy followed by surgery plus concurrent chemoradiotherapy or cystectomy for muscle-invasive bladder cancer: preliminary results of a prospective phase II stude. J Urol. 2020 April; 203:1085. DOI: 10.1097/JU.0000000000000953.07).
8. Nathan Suskovic N, Raldow A, Royce T, et al. PD55-03 cost-effectiveness of radical cystectomy vs. Trimodality therapy for muscle-invasive bladder cancer. J Urol. 2020 April; 203:1182-1183. DOI: 10.1097/JU.0000000000000965.03).
9. European Association of Urology. Guidelines 2020 edition.
10. Elsayed A, Zhe Jing Z, Osei J, et al. PD55-10 outcomes of robot-assisted radical cystectomy in North America vs Europe: results from the international robotic cystectomy consortium. J Urol. 2020 April; 203:1186. DOI: 10.1097/JU.0000000000000965.010).
11. Vuky J, Balar AV, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Jour. Clin. Onc. 2020 August,38 (23):2658-2666. Doi.org/10.1200/JCO.19.01213).
12. Grivas P, Plimack ER, Balar AV, et al. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Eur Urol Onc. 2020 June, 3 (3):351. DOI.org/10.1016/j.euo.2020.02.009).
13. Necchi A, Raggi D, Bandini M, et al. PD51-01 interim results of PEANUT: an open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab- paclitaxel) fs salvage therapy for metastatic urothelial carcinoma (UC). J Urol. 2020 April; 203:1083. DOI: 10.1097/JU.0000000000000953.01.
14. Biyani CS, Pecanka J, Rouprêt M, et al. Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. Eur Urol. 2020 May.77 (5):601-610. DOI.org/10.1016/j.eururo.2019.11.015.
15. Gillessen S, Powles T. Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic. Eur Urol. 2020 June. 77 (6):667-668. DOI.org/10.1016/j.eururo.2020.03.026
16. Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. Eur Urol, 2020 Apr, 77(6):663-666. DOI.org/10.1016/j.eururo.2020.03.027
17. Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort† : Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2020 February. 77(2): 223-250. DOI.org/10.1016/j.eururo.2019.09.035.
